| Income Statement | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Revenue | 8,260 | 29,053 | 124,795 | 61,280 |
| Cost of revenues | 1,285 | 911 | 15,560 | 13,128 |
| Research and development (includes 47,867, 39,780 and 32,400 of share-based compensation expense for the years ended march 31, 2026, 2025 and 2024, respectively) | 681,812 | 550,413 | 501,736 | 525,215 |
| Acquired in-process research and development | 0 | 0 | 26,450 | 97,749 |
| Selling, general and administrative (includes 164,841 and 186,603 of share-based compensation expense for the years ended march 31, 2024 and 2023, respectively) | NaN | NaN | 687,443 | 600,506 |
| General and administrative (includes 298,297, 239,505, and 154,873 of share-based compensation expense for the years ended march 31, 2026, 2025 and 2024, respectively) | 610,466 | 591,410 | NaN | NaN |
| Total operating expenses | 1,293,563 | 1,142,734 | 1,231,189 | 1,236,598 |
| Gain on sale of telavant net assets | 0 | 110,387 | 5,348,410 | NaN |
| Gain on litigation settlement | 770,235 | NaN | NaN | NaN |
| (loss) income from operations | -515,068 | -1,003,294 | 4,242,016 | -1,175,318 |
| Change in fair value of investments | 105,046 | 55,186 | -47,973 | -20,815 |
| Gain on sale of investment | NaN | NaN | NaN | 0 |
| Change in fair value of debt and liability instruments | NaN | NaN | -78,943 | -78,001 |
| Gain on termination of sumitomo options | NaN | NaN | NaN | 0 |
| Change in fair value of liability instruments | -47,704 | 15,756 | NaN | NaN |
| Gain on deconsolidation of subsidiaries | 11,027 | 3,108 | 32,772 | 29,276 |
| Interest income | NaN | 258,375 | 146,425 | 32,184 |
| Interest expense | NaN | NaN | 34,778 | 27,968 |
| Interest income | 178,109 | NaN | NaN | NaN |
| Other (income) expense, net | 4,012 | -10,721 | -6,089 | 15,808 |
| (loss) income from continuing operations before income taxes | -264,578 | -681,590 | 4,253,430 | -1,224,834 |
| Income tax expense | 133,329 | 48,174 | 22,224 | 5,190 |
| (loss) income from continuing operations, net of tax | -397,907 | -729,764 | 4,231,206 | -1,230,024 |
| Revenue, net | NaN | 75,437 | NaN | NaN |
| Cost of revenues | NaN | 12,116 | NaN | NaN |
| Research and development | NaN | 24,307 | NaN | NaN |
| Selling, general and administrative | NaN | 119,879 | NaN | NaN |
| Total operating expenses | NaN | 156,302 | NaN | NaN |
| Loss from operations | NaN | -80,865 | NaN | NaN |
| Gain on sale of subsidiary interests | NaN | 376,506 | NaN | NaN |
| Change in fair value of debt | NaN | 97,322 | NaN | NaN |
| Interest expense | NaN | 30,556 | NaN | NaN |
| Other income, net | NaN | 11,257 | NaN | NaN |
| Income (loss) from discontinued operations before income taxes | NaN | 373,664 | NaN | NaN |
| Income tax expense | NaN | 634 | NaN | NaN |
| Income (loss) from discontinued operations, net of tax | 0 | 373,030 | 0 | 114,561 |
| Net (loss) income | -397,907 | -356,734 | 4,231,206 | -1,115,463 |
| Net loss attributable to noncontrolling interests | -98,136 | -184,753 | -117,720 | -106,433 |
| Net (loss) income attributable to roivant sciences ltd | -299,771 | -171,981 | 4,348,926 | -1,009,030 |
| Basic EPS | -0.43 | -0.24 | 5.55 | -1.42 |
| Diluted EPS | -0.54 | -0.24 | 5.23 | -1.42 |
| Basic Average Shares | 693,864,530 | 725,395,624 | 783,248,906 | 712,791,115 |
| Diluted Average Shares | 693,864,530 | 725,395,624 | 831,049,444 | 712,791,115 |
Roivant Sciences Ltd. (ROIV)
Roivant Sciences Ltd. (ROIV)